

# Christian H Brandts

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8010177/publications.pdf>

Version: 2024-02-01

52  
papers

4,578  
citations

236925  
25  
h-index

182427  
51  
g-index

53  
all docs

53  
docs citations

53  
times ranked

6654  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intracranial hemorrhage in newly diagnosed nonâ€promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy. <i>European Journal of Haematology</i> , 2022, 108, 125-132.	2.2	7
2	SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. <i>Blood</i> , 2022, 139, 538-553.	1.4	27
3	Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations. <i>Annals of Hematology</i> , 2022, 101, 1703-1710.	1.8	3
4	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. <i>Leukemia</i> , 2021, 35, 2517-2525.	7.2	40
5	Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy. <i>Annals of Hematology</i> , 2021, 100, 1159-1167.	1.8	6
6	Minimized combinatorial CRISPR screens identify genetic interactions in autophagy. <i>Nucleic Acids Research</i> , 2021, 49, 5684-5704.	14.5	31
7	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	9.4	125
8	Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy. <i>Annals of Hematology</i> , 2021, 100, 2603-2611.	1.8	1
9	Metabolic Rewiring Is Essential for AML Cell Survival to Overcome Autophagy Inhibition by Loss of ATG3. <i>Cancers</i> , 2021, 13, 6142.	3.7	5
10	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	7.2	46
11	Selective Autophagy in Normal and Malignant Hematopoiesis. <i>Journal of Molecular Biology</i> , 2020, 432, 261-282.	4.2	21
12	Use of carbapenems and glycopeptides increases risk for <i>Clostridioides difficile</i> infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy. <i>Annals of Hematology</i> , 2020, 99, 2547-2553.	1.8	7
13	Distinct immune evasion in <sc>APOBEC</sc>-enriched, <sc>HPV</sc>-negative <sc>HNSCC</sc>. <i>International Journal of Cancer</i> , 2020, 147, 2293-2302.	5.1	10
14	Reducing the red blood cell transfusion threshold from 8Â°0 g/dl to 7Â°0 g/dl in acute myeloid leukaemia patients undergoing induction chemotherapy reduces transfusion rates without adversely affecting patient outcome. <i>Vox Sanguinis</i> , 2020, 115, 570-578.	1.5	6
15	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 2488-2495.	8.2	23
16	Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation. <i>Cell Reports</i> , 2019, 27, 2022-2028.e3.	6.4	44
17	Innovating the outreach of comprehensive cancer centers. <i>Molecular Oncology</i> , 2019, 13, 619-623.	4.6	8
18	Conservation of structure, function and inhibitor binding in UNC-51-like kinase 1 and 2 (ULK1/2). <i>Biochemical Journal</i> , 2019, 476, 875-887.	3.7	37

#	ARTICLE	IF	CITATIONS
19	Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy. <i>Blood</i> , 2019, 133, 168-179.	1.4	83
20	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Nonâ€“High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 605-612.	1.6	299
21	SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment. <i>PLoS ONE</i> , 2017, 12, e0180401.	2.5	2
22	The Phosphatases STS1 and STS2 Regulate Hematopoietic Stem and Progenitor Cell Fitness. <i>Stem Cell Reports</i> , 2015, 5, 633-646.	4.8	11
23	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1691-1699.	10.7	347
24	Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study. <i>Blood</i> , 2015, 126, 3789-3789.	1.4	3
25	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	27.0	1,284
26	Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3110-3118.	1.6	290
27	Interferon-Î³ impairs proliferation of hematopoietic stem cells in mice. <i>Blood</i> , 2013, 121, 3578-3585.	1.4	172
28	Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1062-1067.	1.3	23
29	SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control. <i>Blood</i> , 2012, 120, 1691-1702.	1.4	27
30	Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 613-620.	2.3	6
31	Sorafenib Versus Placebo in Addition to Standard Therapy in Adult Patients â‰¥60 Years with Newly Diagnosed Acute Myeloid Leukemia: Results From the Randomized-Controlled Soraml Trial. <i>Blood</i> , 2012, 120, 144-144.	1.4	4
32	ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSC. <i>Blood</i> , 2012, 120, 6-6.	1.4	18
33	Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia â€” A Randomised SAL Pilot Study. <i>PLoS ONE</i> , 2012, 7, e52695.	2.5	25
34	AML1/ETO induces self-renewal in hematopoietic progenitor cells via the Groucho-related amino-terminal AES protein. <i>Blood</i> , 2011, 117, 4328-4337.	1.4	34
35	Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling. <i>Experimental Hematology</i> , 2011, 39, 591-600.	0.4	23
36	Adaptor protein Lnk inhibits c-Fms-mediated macrophage function. <i>Journal of Leukocyte Biology</i> , 2010, 88, 699-706.	3.3	27

#	ARTICLE	IF	CITATIONS
37	SOCS1 Cooperates with FLT3-ITD In the Development of Myeloproliferative Disease by Promoting the Escape From External Cytokine Control.. Blood, 2010, 116, 1054-1054.	1.4	0
38	Mislocalized Activation of Oncogenic RTKs Switches Downstream Signaling Outcomes. Molecular Cell, 2009, 36, 326-339.	9.7	278
39	Oncogenic Signaling in Acute Myeloid Leukemia. Current Drug Targets, 2007, 8, 237-246.	2.1	10
40	Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Molecular Cancer Therapeutics, 2006, 5, 3105-3112.	4.1	26
41	Constitutive Activation of Akt by Flt3 Internal Tandem Duplications Is Necessary for Increased Survival, Proliferation, and Myeloid Transformation. Cancer Research, 2005, 65, 9643-9650.	0.9	205
42	Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood, 2005, 105, 3699-3706.	1.4	99
43	RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood, 2005, 105, 2107-2114.	1.4	70
44	Phosphorylation-independent Stabilization of p27 by the Phosphoinositide 3-Kinase Pathway in Glioblastoma Cells. Journal of Biological Chemistry, 2005, 280, 12012-12019.	3.4	8
45	Identification of Metastasis-Associated Receptor Tyrosine Kinases in Non-Small Cell Lung Cancer. Cancer Research, 2005, 65, 1778-1782.	0.9	124
46	Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discovery Today, 2004, 9, 759-768.	6.4	46
47	High-Throughput Analysis of Genome-Wide Receptor Tyrosine Kinase Expression in Human Cancers Identifies Potential Novel Drug Targets. Clinical Cancer Research, 2004, 10, 1241-1249.	7.0	107
48	Constitutive Activation of Akt and mTOR by Flt3 Internal Tandem Duplications Mediates Myeloid Leukemogenesis and Can Be Inhibited by Rapamycin.. Blood, 2004, 104, 2532-2532.	1.4	8
49	Replication-selective viruses for cancer therapy. Journal of Molecular Medicine, 2002, 80, 163-175.	3.9	76
50	Decreasing chloroquine resistance in Plasmodium falciparum isolates from Gabon. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 554-556.	1.8	7
51	Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nature Medicine, 2000, 6, 1128-1133.	30.7	171
52	Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet, The, 1997, 350, 704-709.	13.7	213